Towards sustainable clinical trials
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39140.623137.BE (Published 29 March 2007) Cite this as: BMJ 2007;334:671
- Sustainable Trials Study Group
- Correspondence to: I Roberts, London School of Hygiene & Tropical Medicine, London WC1E 7HTcrash{at}Lshtm.ac.uk
- Accepted 30 January 2007
Greenhouse gases are changing the global climate, with serious implications for health and ecosystems.1 2 All sectors of the economy, including the health sector, must act to reduce greenhouse gas emissions.3 High income countries need to cut emissions by about 90% by 2030 to limit the global average increase in temperature to 2°C, and thus reduce the risk of the most serious consequences.4
The Sustainable Trials Study Group was convened by the London School of Hygiene & Tropical Medicine to find ways of reducing greenhouse gas emissions from clinical trials. This international health research institution has an extensive research programme on the links between environment and health. A sustainability group was established to reduce the institution's carbon footprint, and this study is a product of its work.
Summary points
Clinical trials contribute substantially to greenhouse gas emissions
The main sources are energy use in research premises and air travel
Renewable energy sources and more efficient energy use would reduce emissions from premises
Simplified trial designs, reduced bureaucracy, and videoconferencing would reduce air travel
The CRASH trial case study
We conducted a carbon audit of the Medical Research Council (MRC) CRASH trial (www.crash.lshtm.ac.uk) with the Edinburgh Centre for Carbon Management (www.eccm.uk.com). The CRASH trial is a multicentre international trial of the effect of corticosteroids on death and disability in 10 008 adults with head injury.5 The trial was coordinated from the London School of Hygiene & Tropical Medicine, and patients were recruited in 49 countries over five years (1999-2004). The drug was made by Pfizer in the United States and the placebo was made in France. Drug and placebo were packed in Wales. Treatment …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.